Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 8-Methoxycoronaridine HCl
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program
Details : The filing of patent representing, novel, non-racemic ibogaine program, MC-808, an atypical psychedelic substance for use in treating a range of central nervous system disorders.
Product Name : MC-808
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 03, 2022
Lead Product(s) : 8-Methoxycoronaridine HCl
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
